Nanexa AB (NANEXA) - Total Liabilities

Latest as of June 2026: Skr21.81 Million SEK ≈ $2.35 Million USD

Based on the latest financial reports, Nanexa AB (NANEXA) has total liabilities worth Skr21.81 Million SEK (≈ $2.35 Million USD) as of June 2026. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Check NANEXA cash and liquid asset ratio to evaluate the company's liquid asset resilience ratio.

Nanexa AB - Total Liabilities Trend (2014–2025)

This chart illustrates how Nanexa AB's total liabilities have evolved over time, based on quarterly financial data. For the complete balance sheet picture, see balance sheet size of Nanexa AB.

Nanexa AB Competitors by Total Liabilities

The table below lists competitors of Nanexa AB ranked by their total liabilities.

Company Country Total Liabilities
Eusu Holdings
KO:000700
Korea ₩84.65 Billion
Ice Make Refrigeration Limited
NSE:ICEMAKE
India Rs3.06 Billion
Endava plc
F:2Y5
Germany €362.92 Million
Gold Resource Corporation
NYSE MKT:GORO
USA $138.38 Million
Kulmbacher Brauerei Aktien-Gesellschaft
MU:KUL
Germany €168.79 Million
Equillium Inc
NASDAQ:EQ
USA $3.57 Million
Unifi Inc
NYSE:UFI
USA $160.50 Million
RiverNorth Managed Duration Municipal Income Fund II Inc.
NYSE:RMMZ
USA $95.41 Million

Liability Composition Analysis (2014–2025)

This chart breaks down Nanexa AB's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. See Nanexa AB balance sheet independence to measure how much of total assets are equity-financed.

Liquidity & Leverage Metrics

Key Metrics Explained

Metric Value Description
Current Ratio 2.89 Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities)
Quick Ratio N/A More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities)
Cash Ratio N/A Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities)
Debt to Equity 0.16 Measures financial leverage (Total Liabilities ÷ Shareholder Equity)
Debt to Assets 0.14 Portion of assets financed with debt (Total Liabilities ÷ Total Assets)

Liability Trends Comparison

This chart compares key liability metrics across different time periods, showing how Nanexa AB's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.

Annual Total Liabilities for Nanexa AB (2014–2025)

The table below shows the annual total liabilities of Nanexa AB from 2014 to 2025.

Year Total Liabilities Change
2025-12-31 Skr36.61 Million
≈ $3.94 Million
+75.21%
2024-12-31 Skr20.90 Million
≈ $2.25 Million
-42.64%
2023-12-31 Skr36.43 Million
≈ $3.92 Million
-40.38%
2022-12-31 Skr61.10 Million
≈ $6.58 Million
+345.88%
2021-12-31 Skr13.70 Million
≈ $1.47 Million
+32.52%
2020-12-31 Skr10.34 Million
≈ $1.11 Million
-2.08%
2019-12-31 Skr10.56 Million
≈ $1.14 Million
-9.05%
2018-12-31 Skr11.61 Million
≈ $1.25 Million
+103.42%
2017-12-31 Skr5.71 Million
≈ $614.26K
+57.47%
2016-12-31 Skr3.62 Million
≈ $390.09K
+109.73%
2015-12-31 Skr1.73 Million
≈ $185.99K
+54.67%
2014-12-31 Skr1.12 Million
≈ $120.25K
--

About Nanexa AB

ST:NANEXA Sweden Drug Manufacturers - Specialty & Generic
Market Cap
$116.93 Million
Skr1.09 Billion SEK
Market Cap Rank
#18691 Global
#324 in Sweden
Share Price
Skr5.88
Change (1 day)
+5.00%
52-Week Range
Skr1.61 - Skr6.33
All Time High
Skr15.20
About

Nanexa AB (publ), a pharmaceutical company, develops injectable drug products in the Nordic countries, Europe, Asia, and North America. The company offers PharmaShell, a drug delivery system based on atomic layer deposition coating technology for controlled release of various types of active pharmaceutical substances. It also develops NEX-22, a glucagon-like peptide-1 analogue liraglutide that ha… Read more